176 related articles for article (PubMed ID: 25973027)
1. Role of ursolic acid chalcone, a synthetic analogue of ursolic acid, in inhibiting the properties of CD133(+) sphere-forming cells in liver stem cells.
Lin RX; Gong LL; Fan LM; Zhao ZK; Yang SL
Int J Clin Exp Pathol; 2015; 8(2):1427-34. PubMed ID: 25973027
[TBL] [Abstract][Full Text] [Related]
2. Loss of ATOH8 Increases Stem Cell Features of Hepatocellular Carcinoma Cells.
Song Y; Pan G; Chen L; Ma S; Zeng T; Man Chan TH; Li L; Lian Q; Chow R; Cai X; Li Y; Li Y; Liu M; Li Y; Zhu Y; Wong N; Yuan YF; Pei D; Guan XY
Gastroenterology; 2015 Oct; 149(4):1068-81.e5. PubMed ID: 26099525
[TBL] [Abstract][Full Text] [Related]
3. An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.
Li M; Zhang L; Ge C; Chen L; Fang T; Li H; Tian H; Liu J; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J
Oncotarget; 2015 Sep; 6(28):25149-60. PubMed ID: 26327240
[TBL] [Abstract][Full Text] [Related]
4. Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma.
Kohga K; Tatsumi T; Takehara T; Tsunematsu H; Shimizu S; Yamamoto M; Sasakawa A; Miyagi T; Hayashi N
J Hepatol; 2010 Jun; 52(6):872-9. PubMed ID: 20395004
[TBL] [Abstract][Full Text] [Related]
5. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma.
Zhu Z; Hao X; Yan M; Yao M; Ge C; Gu J; Li J
Int J Cancer; 2010 May; 126(9):2067-78. PubMed ID: 19711346
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of transcription factor Ikaros on the expression of liver cancer stem cell marker CD133 in hepatocellular carcinoma.
Zhang L; Li H; Ge C; Li M; Zhao FY; Hou HL; Zhu MX; Tian H; Zhang LX; Chen TY; Jiang GP; Xie HY; Cui Y; Yao M; Li JJ
Oncotarget; 2014 Nov; 5(21):10621-35. PubMed ID: 25301737
[TBL] [Abstract][Full Text] [Related]
7. BMP4 administration induces differentiation of CD133+ hepatic cancer stem cells, blocking their contributions to hepatocellular carcinoma.
Zhang L; Sun H; Zhao F; Lu P; Ge C; Li H; Hou H; Yan M; Chen T; Jiang G; Xie H; Cui Y; Huang X; Fan J; Yao M; Li J
Cancer Res; 2012 Aug; 72(16):4276-85. PubMed ID: 22773665
[TBL] [Abstract][Full Text] [Related]
8. Transient mTOR inhibition facilitates continuous growth of liver tumors by modulating the maintenance of CD133+ cell populations.
Yang Z; Zhang L; Ma A; Liu L; Li J; Gu J; Liu Y
PLoS One; 2011; 6(12):e28405. PubMed ID: 22145042
[TBL] [Abstract][Full Text] [Related]
9. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations.
Ma S; Chan KW; Lee TK; Tang KH; Wo JY; Zheng BJ; Guan XY
Mol Cancer Res; 2008 Jul; 6(7):1146-53. PubMed ID: 18644979
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of tumorigenic liver cancer stem/progenitor cells.
Ma S; Chan KW; Hu L; Lee TK; Wo JY; Ng IO; Zheng BJ; Guan XY
Gastroenterology; 2007 Jun; 132(7):2542-56. PubMed ID: 17570225
[TBL] [Abstract][Full Text] [Related]
11. Arsenic trioxide induces differentiation of CD133+ hepatocellular carcinoma cells and prolongs posthepatectomy survival by targeting GLI1 expression in a mouse model.
Zhang KZ; Zhang QB; Zhang QB; Sun HC; Ao JY; Chai ZT; Zhu XD; Lu L; Zhang YY; Bu Y; Kong LQ; Tang ZY
J Hematol Oncol; 2014 Mar; 7():28. PubMed ID: 24678763
[TBL] [Abstract][Full Text] [Related]
12. A Novel Function for KLF4 in Modulating the De-differentiation of EpCAM
Karagonlar ZF; Akbari S; Karabicici M; Sahin E; Avci ST; Ersoy N; Ates KE; Balli T; Karacicek B; Kaplan KN; Celiker C; Atabey N; Erdal E
Cells; 2020 May; 9(5):. PubMed ID: 32408542
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the cancer stem cells-like properties by arsenic trioxide, involved in the attenuation of endogenous transforming growth factor beta signal.
Li Y; Jiang F; Liu Q; Shen J; Wang X; Li Z; Zhang J; Lu X
Toxicol Sci; 2015 Jan; 143(1):156-64. PubMed ID: 25304214
[TBL] [Abstract][Full Text] [Related]
14. The CD133+ subpopulation of the SW982 human synovial sarcoma cell line exhibits cancer stem-like characteristics.
Liu A; Feng B; Gu W; Cheng X; Tong T; Zhang H; Hu Y
Int J Oncol; 2013 Apr; 42(4):1399-407. PubMed ID: 23416969
[TBL] [Abstract][Full Text] [Related]
15. Sphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell lines.
Cao L; Zhou Y; Zhai B; Liao J; Xu W; Zhang R; Li J; Zhang Y; Chen L; Qian H; Wu M; Yin Z
BMC Gastroenterol; 2011 Jun; 11():71. PubMed ID: 21669008
[TBL] [Abstract][Full Text] [Related]
16. Positive correlation of Oct4 and ABCG2 to chemotherapeutic resistance in CD90(+)CD133(+) liver cancer stem cells.
Jia Q; Zhang X; Deng T; Gao J
Cell Reprogram; 2013 Apr; 15(2):143-50. PubMed ID: 23438193
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of NOTCH signaling pathway chemosensitizes HCC CD133
Hemati H; Kaur J; Sobti RC; Trehanpati N
Biochem Biophys Res Commun; 2020 May; 525(4):941-947. PubMed ID: 32173531
[TBL] [Abstract][Full Text] [Related]
18. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1.
Ma S; Tang KH; Chan YP; Lee TK; Kwan PS; Castilho A; Ng I; Man K; Wong N; To KF; Zheng BJ; Lai PB; Lo CM; Chan KW; Guan XY
Cell Stem Cell; 2010 Dec; 7(6):694-707. PubMed ID: 21112564
[TBL] [Abstract][Full Text] [Related]
19. Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells.
Hsu HS; Huang PI; Chang YL; Tzao C; Chen YW; Shih HC; Hung SC; Chen YC; Tseng LM; Chiou SH
Cancer; 2011 Jul; 117(13):2970-85. PubMed ID: 21225866
[TBL] [Abstract][Full Text] [Related]
20. In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines.
Zito G; Richiusa P; Bommarito A; Carissimi E; Russo L; Coppola A; Zerilli M; Rodolico V; Criscimanna A; Amato M; Pizzolanti G; Galluzzo A; Giordano C
PLoS One; 2008; 3(10):e3544. PubMed ID: 18958156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]